Klivira
Request demo

Optimizing Infectious Disease 7-Day Urgent Prior Auth Workflows

For critical patient pathways in infectious disease, a streamlined 7-day urgent prior auth process is essential to ensure timely access to life-saving therapies.

Managing urgent prior authorizations for high-cost antivirals, antifungals, and OPAT in infectious disease presents unique challenges. Klivira’s platform automates these critical workflows, ensuring compliance with the CMS-0057-F 7-day urgent decision timeline and accelerating patient access to necessary treatments.

The Criticality of Timely Access in Infectious Disease

Infectious disease (ID) conditions often demand rapid intervention, where delays in starting high-cost antivirals (e.g., for HIV, HCV) or antifungals, or initiating Outpatient Parenteral Antimicrobial Therapy (OPAT), can lead to rapid disease progression, increased morbidity, and higher downstream costs. This clinical reality makes the CMS-0057-F 7-day urgent decision timeline particularly impactful for ID patient outcomes, necessitating efficient prior authorization processes.

Common Infectious Disease Urgent PA Triggers

  • High-cost antiviral regimens (e.g., for HIV, Hepatitis C, COVID-19)
  • Systemic antifungal therapies for immunocompromised patients or severe infections
  • Initiation of Outpatient Parenteral Antimicrobial Therapy (OPAT)
  • Novel broad-spectrum antibiotics for multi-drug resistant infections
  • Advanced diagnostic imaging (e.g., PET/CT for deep-seated infections) when results are time-sensitive for treatment planning

Streamlining EMR and Payer Interactions for ID Urgent PAs

Klivira automates the extraction of critical clinical data from EMRs via SMART on FHIR, including ID consultation notes, microbiology results, viral load counts, and resistance testing. This data supports urgent PA submissions through X12 278 transactions, ePA portals, or direct payer channels, ensuring payers receive comprehensive documentation aligned with IDSA, HIVMA, or AASLD guidelines for rapid review and decision-making.

Essential Documentation for Expedited ID Prior Authorizations

  • Infectious Disease specialist consultation notes and treatment plans
  • Specific microbiology reports (e.g., culture and sensitivity), viral load and genotype testing results
  • Documented treatment history, including prior therapy failures or intolerances
  • Relevant imaging reports (e.g., CT, MRI, PET scans) supporting diagnosis and severity
  • Justification referencing established clinical guidelines (e.g., IDSA, AASLD, HIVMA) for the requested therapy

Klivira's Automation: Meeting the CMS-0057-F Mandate for ID

Klivira's platform is engineered to manage the urgency inherent in infectious disease 7-day urgent prior auth workflows. It automates urgent submission pathways, provides real-time timeline tracking against the CMS-0057-F mandate, and triggers automated escalation alerts to ensure critical decisions on high-cost antivirals, antifungals, or OPAT are rendered within the required timeframe, minimizing administrative burden and accelerating patient care.

Frequently asked questions

How does Klivira handle the 7-day timeline for urgent ID prior authorizations?

Klivira automates the urgent submission process, leveraging direct integrations and ePA channels. Our platform provides real-time timeline tracking with automated alerts and escalation protocols to ensure all steps are completed within the CMS-0057-F mandated 7-day window, minimizing delays for critical infectious disease therapies.

What specific infectious disease treatments benefit most from urgent PA automation?

High-cost antiviral regimens for conditions like HIV and Hepatitis C, systemic antifungal therapies for severe or immunocompromised patients, and the initiation of Outpatient Parenteral Antimicrobial Therapy (OPAT) are among the ID treatments that critically benefit from expedited prior authorization automation, ensuring rapid patient access.

Does Klivira integrate with our EMR to pull infectious disease patient data?

Yes, Klivira integrates with major EMR systems via SMART on FHIR and other secure APIs. This allows for automated, compliant extraction of relevant clinical data, such as ID consultation notes, lab results, and treatment history, directly into the prior authorization request, streamlining the documentation process for infectious disease cases.

How does Klivira ensure compliance with CMS-0057-F for ID urgent PAs?

Klivira's workflow engine is designed to enforce adherence to the CMS-0057-F requirements for urgent prior authorizations. This includes automated timeline management, documentation prompts for urgent criteria, and comprehensive audit trails for every step of the PA process, providing transparency and supporting regulatory compliance for infectious disease cases.

Can Klivira manage urgent prior authorizations for OPAT?

Absolutely. Klivira specializes in automating prior authorizations for complex therapies like OPAT. Our system captures the specific clinical criteria, documentation requirements (e.g., infection type, patient stability, home care plan), and urgent submission pathways necessary to secure timely approvals for Outpatient Parenteral Antimicrobial Therapy in infectious disease patients.

Related coverage

Other infectious-disease prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo